ABNOM
☆ AI Dermatology — Free Service
I 2022 Stiftung Warentest-resultatene fra Tyskland var forbrukertilfredsheten med ModelDerm bare litt lavere enn med betalte telemedisinkonsultasjoner.
I 2022 Stiftung Warentest-resultatene fra Tyskland var forbrukertilfredsheten med ModelDerm bare litt lavere enn med betalte telemedisinkonsultasjoner.
relevance score : -100.0%
ReferencesQ‑switched Nd:YAG‑laseren er kjent for å behandle nevus av Ota og lignende tilstander effektivt. Vi gjennomførte en studie for å undersøke hvor godt en high‑fluence 1064 nm Q‑switched Nd:YAG‑laser fungerer på mongolske flekker i uvanlige områder, uten å lysne huden. Vi inkluderte 61 pasienter med slike flekker og vurderte totalt 70 lesjoner. Halvparten av lesjonene ble behandlet med laser, mens resten ble stående ubehandlet for sammenligning. Resultatene ble evaluert med en skala og med en enhet kalt Mexameter® for å måle melaninnivåer. Pasientene ble fulgt opp i gjennomsnitt 14 måneder i behandlingsgruppen og 18 måneder i observasjonsgruppen. På studiens slutt fant vi signifikante forskjeller i skalaskår og melaninnivåer mellom de behandlede og ubehandlede gruppene, der den laserbehandlede gruppen viste bedre resultater. High‑fluence Q‑switched Nd:YAG‑laseren, uten å forårsake lysere hud, viste seg både effektiv og trygg for behandling av disse uvanlige mongolske flekkene.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
Vi studerte effektiviteten og sikkerheten ved bruk av en spesifikk laserbehandling for ABNOM, og undersøkte hvilke faktorer som kan påvirke resultatet. Studien inkluderte 110 pasienter med ABNOM som fikk mellom to og ni laserbehandlinger. Vi fant at behandlingen var mer effektiv jo flere behandlinger som ble gitt, men den var mindre effektiv hos eldre pasienter. Resultatene var også bedre hos pasienter med lysere hud (type III) og hos områder med mindre enn 10 cm² berørt hud. Når melasma forekom sammen med ABNOM, ble behandlingen mindre effektiv. Farge eller antall berørte områder påvirket ikke resultatet. Omtrent 10 % av pasientene utviklet hyperpigmentering etter behandlingen. Tidlig multippelbehandling ga gode resultater. Eldre pasienter med mørkere hud og eksisterende hyperpigmentering har høyere risiko for å utvikle nye mørkere flekker etter behandlingen. For pasienter med både ABNOM og melasma anbefales bruk av en lavenergilaser for å unngå forverring av melasma.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
○ Behandling
Blekemidler hjelper sjelden. I motsetning til melasma kan ABNOM forbedres med laserbehandling og fjernes uten tilbakefall. Laserbehandling kan utføres 10–20 ganger for å behandle ABNOM.
#QS1064 laser